Hormone replacement therapy in breast cancer survivors

Annals of the New York Academy of Sciences

Volumn 1092, Issue , 2006, Pages 349-360

  Xydakis, Antonios M ^a   Sakkas, Evangelos Gr ^a   Mastorakos, George ^a,b  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

Breast cancer survivors; Hormone therapy; Menopausal symptoms

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; TAMOXIFEN; TIBOLONE;

BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVOR; CONFERENCE PAPER; ESTROGEN THERAPY; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; LYMPH NODE; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PREMENOPAUSE; TREATMENT DURATION; TREATMENT OUTCOME; BREAST TUMOR; FEMALE; MENOPAUSE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; SURVIVOR;

BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVORS;

EID: 34247271307     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1365.032     Document Type: Conference Paper

References (23)

1. BIGLIA, N., M. COZZARELLA, F. CACCIARI, et al. 2003. Menopause after breast cancer: a survey on breast cancer survivors. Maturitas 45: 29-38.
2. VASSILOPOULOU-SELLIN, R. & M.J. KLEIN. 1996. Estrogen replacement therapy after treatment for localized breast carcinoma: patients responses and opinions. Cancer 78:1043-1048.
3. HULLEY, S., D. GRADY, T. BUSH, et al. 1998. Randomized trial of oestrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280: 605-613.
4. GRADY, D., D. HERRINGTON, V. BITTNER, et al. 2002. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and oestrogen-progestin replacement study follow-up (HERS II). JAMA 288:49-57.
5. WRITING GROUP FOR THE WOMEN'S HEALTH INITIATIVE INVESTIGATORS. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized control trial. JAMA 288: 321-333.
6. BERAL, V. MILLION WOMEN 'S STUDY COLLABORATORS. 2003. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 362: 419-427.
7. THE WOMEN'S HEALTH INITIATIVE STEERING COMMITTEE. 2004. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 291:1701-1712.
8. BIGLIA, N., L. SGRO, E. DEFABIANI, et al. 2005. The influence of hormone replacement therapy on the pathology of breast cancer. Eur. J. Surg. Oncol. 31: 467-472.
9. FLETCHER, A.S., B. ERBAS, A.M. KAVANAGH, et al. 2005. Use of hormone replacement therapy (HRT) and survival following breast cancer diagnosis. Breast 14: 192-200.
10. MARSDEN, J., M. WHITEHEAD, R. A'HERN, et al. 2000. Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? Fertil. Steril. 73: 292-299.
11. POWLES, T.J., T. HICKISH, S. CASEY, et al. 1993. Hormone replacement after breast cancer. Lancet 342: 60-61.
12. DISAIA, P.J., E.A. GROSEN, F. ODICINO, et al. 1995. Replacement therapy for breast cancer survivors. A pilot study. Cancer 76: 2075-2078.
13. DISAIA, P.J., E.A. GROSEN, T. KUROSAKI, et al. 1996. Hormone replacement therapy in breast cancer survivors: a cohort study. Am. J. Obstet. Gynecol. 174: 1494-1498.
14. VASSILOPOULOU-SELLIN, R., R. THERIAULT & M.J. KLEIN. 1997. Estrogen replacement therapy in women with prior diagnosis and treatment of breast cancer. Gynecol. Oncol. 65: 89-93.
15. O'MEARA, E.S., A. ROSSING, J.R. DALING, et al. 2001. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J. Natl. Cancer Inst 93: 754-762.
16. BECKMANN, M.W., D. JAP, S. DJAHANSOUZI, et al. 2001. Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates. Oncology 60: 199-206.
17. DURNA, E.M., B.G. WREN, G.Z. HELLER, et al. 2002. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Med. J. Aust. 177: 347-351.
18. MARSDEN, J. 2002. Hormone-replacement therapy and breast cancer. Lancet Oncol. 3: 303-311.
19. CHANG, J., T. POWLES, S. ASHLEY, et al. 1996. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann. Oncol. 7: 671-675.
20. COL, N., L. HIROTA, R. ORR, et al. 2001. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J. Clin. Oncol. 19: 2357-2363.
21. VASSILOPOULOU-SELLIN, R., D.S. COHEN, G.N. HORTOBAGYI, et al. 2002. Estrogen replacement therapy for menopausal women with a history of breast carcinoma. Cancer 95: 1817-1826.
22. STEERING COMMITTEE AND DMC OF HABITS. 2004. HABITS (hormonal replacement therapy after breast cancer- is it safe?), a randomized comparison: trial stopped. Lancet 363: 453-455.
23. RUTQVIST, L., D. CEDERMARK, U. GLAS, et al. 1987. The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res. Treat. 10: 255-266.